Oestrogens and overactive bladder

Neurourology and Urodynamics

Volumn 33, Issue 7, 2014, Pages 1086-1091

  Robinson, Dudley ^a   Cardozo, Linda ^a   Milsom, Ian ^b   Pons, Montserrat Espuna ^c   Kirby, Michael ^d   Koelbl, Heinz ^e   Vierhout, Mark ^f  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

^c HOSPITAL CLÍNIC   (Spain)

^d Prostate Centre   (United Kingdom)

^e UNIV KLIN FÜR FRAUENHEILKUNDE   (Austria)

^f RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

hormone replacement therapy; oestrogen; overactive bladder

Indexed keywords

ESTROGEN;

ESTROGEN THERAPY; FEMALE; HUMAN; POSTMENOPAUSE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; HUMANS; POSTMENOPAUSE; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 84906069083     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.22464     Document Type: Review

References (50)

1. Iosif S, Batra S, Ek A, et al. Estrogens receptors in the human female lower urinary tract. Am J Obstet Gynaecol 1981; 141: 817-20.
2. Batra SC, Iosif LS,. Progesterone receptors in the female urinary tract. J Urol 1987; 138: 130-34.
3. Iosif C, Bekassy Z,. Prevalence of genitourinary symptoms in the late menopause. Acta Obstet Gynaecol Scan 1984; 63: 257-60.
4. Teleman PM, Persson J, Mattiasson A, et al. The relation between urinary incontinence and steroid hormone levels in perimenopausal women. A report from the women's health in the Lund area (WHILA) study. Acta Obstet Gynaecol Scand 2009; 88: 927-32.
5. Gopal M, Sammel MD, Arya LA, et al. Association of change in estradiol to lower urinary tract symptoms during the menopausal transition. Obstet Gynaecol 2008; 112: 1045.
6. Haylen BT, de Ridder D, Freeman RM, et al. An International Urogynaecological Association (IUGA)/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J 2010; 21: 5-26.
7. Stewart WF, Corey R, Herzog AR, et al. Prevalence of overactive bladder in women: Results from the NOBLE program. Int Urogynaecol J 2001; 12: S66.
8. Milsom I, Abrams P, Cardozo L, et al. How widespread are the symptoms of overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001; 87: 760-66.
9. Anderson KE,. The overactive bladder: Pharmacologic basis of drug treatment. Urology 1997; 50: 74-89.
10. Hashim H, Abrams P,. Is the bladder a reliable witness for predicting detrusor overactivity ? J Urol 2006; 175: 191-5.
11. Grady D, Brown JS, Vittinghoff E, et al. Postmenopausal hormones and incontinence: The heart and estrogen/progestin replacement study. Obstet Gynaecol 2001; 97: 116-20.
12. Grodstein F, Lifford K, Resnick NM, et al. Postmenopausal hormone therapy and risk of developing urinary incontinence. Obstet Gynaecol 2004; 103: 254-60.
13. Hendrix SL, Cochrane BR, Nygaard IE, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA 2005; 293: 935-48.
14. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: Randomised trial. BMJ 2012; 345: e6409.
15. Andersson K, Mattsson LA, Rybo G, et al. Intrauterine release of levonorgestrel-A new way of adding progestogen in hormone replacement therapy. Obstet Gynaecol 1992; 79: 963-7.
16. Varila E, Wahlstrom T, Rauramo I,. A 5 year follow up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. Fertil Steril 2001; 76: 969-73.
17. Nappi RE, Davis SR,. The use of homone therapy for the maintenance of urogynaecological and sexual health post WHI. Climacteric 2012; 15: 267-74.
18. Keane DP, Sims TJ, Abrams P, et al. Analysis of collagen status in premenopausal nulliparous women with genuine stress incontinence. Br J Obstet Gynaecol 1997; 104: 994-8.
19. Falconer C, Blomgren B, Johansson O, et al. Different organisation of collagen fibrils in stress incontinent women of fertile age. Acta Obstet Gynaecol Scand 1998; 77: 87-94.
20. Edwall L, Carlstrom K, Jonasson AF,. Endocrine status and markers of collagen synthesis and degradation in serum and urogenital tissue from women with and without stress urinary incontinence. Neurourol Urodyn 2007; 26: 410-5.
21. Jackson S, James M, Abrams P,. The effect of estradiol on vaginal collagen metabolism in postmenopausal women with genuine stress incontinence. Br J Obstet Gynaecol 2002; 109: 339-44.
22. Aikawa K, Sugino T, Matsumoto S, et al. The effect of ovariectomy and estradiol on rabbit bladder smooth muscle contraction and morphology. J Urol 2003; 170: 634-7.
23. Skala CE, Poetry IB, Albrich SB, et al. The effect of hormonal status on the expression of estrogen and progesterone receptors in vaginal wall and periurethral tissue in urogynaecological patients. Eur J Obstet Gynaecol Reprod Biol 2010; 153: 99-103.
24. Cody JD, Richardson K, Moehrer B, et al. Estrogen therapy for urinary incontinence in postmenopausal women. Cochrane Database Syst Rev 2009; Issue 4. Art. No: CD001405. DOI: 10.1002/14651858.CD001405.pub2
25. Moehrer B, Hextall A, Jackson S,. Estrogens for urinary incontinence. Cochrane Database Syst Rev 2003; CD001405.
26. Rees M, Perez-Lopez F, Ceasu I, et al. EMAS clinical guideline: Low dose vaginal estrogen for postmenopausal vaginal atrophy. Maturitas 2012; 73: 171-4.
27. Pfeiler G, Glatz C, Konigsberg R, et al. Vaginal estriol to overcome side effects of aromatase inhibitors in breast cancer patients. Climacteric 2011; 14: 339-44.
28. Brading AF, Turner WH,. The unstable bladder: Towards a common mechanism. Br J Urol 1994; 73: 3-8.
29. Brading AF,. A myogenic basis for the overactive bladder. Urology 1997; 50: 57-67.
30. Hong SK, Yang JH, Kim TB, et al. Effects of ovariectomy and estrogen replacement on the function an dexpression of Rho-kinase in rat bladder smooth muscle. BJU Int 2006; 98: 1114-7.
31. Yoshida J, Aikawa K, Yoshimura Y, et al. The effects of ovariectomy and estrogen replacement on acetylcholine release from nerve fibres and passive stretch induced acetylcholine release in female rats. Neurourol Urodyn 2007; 26: 1050-5.
32. Ferguson DR, Kennedy I, Burton TJ,. ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes-A possible sensory mechanism ? J Physiol 1997; 505: 503-11.
33. Maggi CA,. Prostanoids as local modulators of reflex micturition. Pharmacol Res 1992; 25: 13-20.
34. Birder LA,. Adrenergic and capsaicin evoked nitric oxide release from urothelium and afferent nerves in urinary bladder. Am J Physiol 1998; 275: F226-9.
35. Andersson KE,. Bladder activation: Afferent mechanisms. Urology 2002; 59: 43-50.
36. Silva C, Ribero MJ, Cruz F,. The effect of intravesical resiniferatoxin in patients with idiopathic detrusor instability suggests that involuntary detrusor contractions are triggered by C-fibre input. J Urol 2002; 168: 575-9.
37. Archer DF,. Efficacy and tolerability of local estrogen therapy for urogenital atrophy. Menopause 2010; 17: 194-203.
38. Griebling TL, Liao Z, Smith PG,. Systemic and topical hormone therapies reduce vaginal innervations density in postmenopausal women. Menopause 2010; 19: 630-5.
39. Tandir Y, Ercan F, Tarcan T,. Exogenous testosterone and estrogen affect bladder tissue contractility and histomorphology differently in rat ovariectomy model. J Sex Med 2011; 8: 1626-37.
40. Yu Y, Shen Z, Zhou X, et al. Effects of steroid hormones on morphology and vascular endothelial growth factor expression in female bladder. Urology 2009; 73: 1210-7.
41. Samsicoe G, Jansson I, Mellstrom D, et al. Urinary incontinence in 75 year old women. Eff Oestriol Acta Obstet Gynaecol Scand 1985; 93: 57.
42. Cardozo LD, Rekers H, Tapp A, et al. Oestriol in the treatment of postmenopausal urgency: A multicentre study. Maturitas 1993; 18: 47-53.
43. Rufford J, Hextall A, Cardozo L, et al. A double-blind placebo controlled trial on the effects of 25mg oestradiol implants on the urge syndrome in postmenopausal women. Int Urogynaecol J Pelvic Floor Dysfunct 2003; 14: 78-83.
44. Benness C, Wise BG, Cutner A, et al. Does low dose vaginal oestradiol improve frequency and urgency in postmenopausal women. Int Urogynaecol J 1992; 3: 281.
45. Eriksen PS, Rasmussen H,. Low dose 17β-oestradiol vaginal tablets in the treatment of atrophic vaginitis: A double-blind placebo controlled study. Eur J Obstet Gynaecol Reprod Biol 1992; 44: 137-44.
46. Simunic V, Banovic I, Ciglar S, et al. Local estrogen treatment in patients with urogenital symptoms. Int J Gynaecol Obstet 2003; 82: 187-97.
47. Cardozo L, Lose G, McClish D, et al. A systematic review of the effects of estrogens for symptoms suggestive of overactive bladder. Acta Obstet Gynaecol Scand 2004; 83: 892-7.
48. Tseng LH, Wang AC, Chang YL, et al. Randomized comparison of tolterodine with vaginal estrogen cream versus tolterodine alone for the treatment of postmenopausal women with overactive bladder syndrome. Neurourol Urodyn 2009; 28: 47-51.
49. Serati M, Salvatore S, Uccella S, et al. Is there a synergistic effect of topical estrogens when administered with antimuscarinics in the treatment of symptomatic detrusor overactivity ? Eur Urol 2009; 55: 713-9.
50. Nelken RS, Ozel BZ, Leegant AR, et al. radomised trial of oestradiol vaginal ring versus oral oxybutynin for the treatment of overactive bladder. Menopause 2011; 18: 962-6.